Valsartan vs entresto?

Question

Accepted Answer

Valsartan vs. Entresto (Sacubitril/valsartan)

(What the two drugs are, how they’re used, how they differ, and what you need to keep an eye on.)

Feature	Valsartan (ARB)	Entresto (Sacubitril/Valsartan, ARNI)
Drug Class	Angiotensin‑Receptor Blocker (ARB)	Neprilysin inhibitor + ARB (Angiotensin‑Neprilysin Inhibitor, ARNI)
Active Ingredients	Valsartan	Sacubitril (pro‑drug → LBQ657) + Valsartan
Key Mechanism	Blocks AT₁ receptors → ↓ vasoconstriction, aldosterone, sympathetic tone	• Sacubitril → ↑ natriuretic peptides (BNP, ANP) → vasodilation, natriuresis, diuresis • Valsartan → same ARB effect as above
Indications	• Primary treatment for hypertension • Heart failure with reduced EF (HFrEF) as an alternative to ACEI/ARB • Diabetic nephropathy (renal protection)	• HFrEF (NYHA class II‑IV) – first‑line therapy per 2017 ACC/AHA & ESC guidelines • Not approved for hypertension alone
Typical Dose	80 mg BID → 160 mg/day → up to 320 mg/day (max)	Start 24/26 mg BID → uptitrated to 49/51 mg BID (max 97/103 mg BID). Initial 24/26 mg is 24 mg sacubitril/26 mg valsartan.
Half‑Life	~6.5 h (valsartan component)	Sacubitril ~1 h, LBQ657 (active metabolite) ~6 h; valsartan ~9 h
Potency in HF	Good, but lower mortality benefit than ARNI	Demonstrated ~20–30 % reduction in CV death & HF hospitalization vs. ACEI (PARADIGM‑HF)
Side‑Effect Profile	• Hypotension • Hyperkalemia • Renal function decline (esp. in CKD) • Rare cough (much lower than ACEIs)	• Hypotension (especially with diuretics/nitrates) • Hyperkalemia • Renal dysfunction (monitor eG

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Valsartan vs entresto?

Valsartan vs. Entresto (Sacubitril/valsartan)